Study of Myasthenic Crisis in China

计划入组 300 人 · 首次发布于 2021 年 4 月 8 日

Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis

计划入组 16 人 · 首次发布于 2024 年 11 月 14 日

Efficacy of IVIG Versus PLEX in Myasthenic Crisis in Syria.

计划入组 50 人 · 首次发布于 2026 年 4 月 16 日

AAV9 based ChAT gene therapy (congenital myasthenic syndrome)

Amifampridine(Firdapse, Ruzurgi, Firdapse (previously Zenas), Amifampridine SERB)

C₅H₇N₃ · Rx

Guanidine

CH₅N₃

Irisys, Inc.

United States

CRISPR Therapeutics

United States

ORASIS PHARMACEUTICALS LTD

Israel

Eculizumab Shows Promise in Treating Thymoma-Associated Myasthenia Gravis

Large-Scale Study Confirms Sugammadex's Safety and Efficacy in Myasthenia Gravis Patients Post-Surgery

Novel Respiratory and EMG Patterns Identified as Reliable Indicators of Dysphagia in Myasthenia Gravis